CY1106156T1 - Νεα χρηση βουδεσονιδης και φορμοτepολης - Google Patents

Νεα χρηση βουδεσονιδης και φορμοτepολης

Info

Publication number
CY1106156T1
CY1106156T1 CY20061101297T CY061101297T CY1106156T1 CY 1106156 T1 CY1106156 T1 CY 1106156T1 CY 20061101297 T CY20061101297 T CY 20061101297T CY 061101297 T CY061101297 T CY 061101297T CY 1106156 T1 CY1106156 T1 CY 1106156T1
Authority
CY
Cyprus
Prior art keywords
budesonide
formotepol
new use
new
formoterol
Prior art date
Application number
CY20061101297T
Other languages
Greek (el)
English (en)
Inventor
Carl-Axel Bauer
Jan Trofast
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20408325&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1106156(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CY1106156T1 publication Critical patent/CY1106156T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CY20061101297T 1997-09-19 2006-09-12 Νεα χρηση βουδεσονιδης και φορμοτepολης CY1106156T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9703407A SE9703407D0 (sv) 1997-09-19 1997-09-19 New use
EP98944373A EP1014993B1 (en) 1997-09-19 1998-09-09 New use for budesonide and formoterol

Publications (1)

Publication Number Publication Date
CY1106156T1 true CY1106156T1 (el) 2011-06-08

Family

ID=20408325

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20061101297T CY1106156T1 (el) 1997-09-19 2006-09-12 Νεα χρηση βουδεσονιδης και φορμοτepολης

Country Status (38)

Country Link
US (2) US7897646B2 (en:Method)
EP (2) EP1014993B1 (en:Method)
JP (1) JP2001517630A (en:Method)
KR (1) KR20010024140A (en:Method)
CN (1) CN1149998C (en:Method)
AR (1) AR013506A1 (en:Method)
AT (2) ATE329599T1 (en:Method)
AU (1) AU757235B2 (en:Method)
BR (1) BR9812325A (en:Method)
CA (1) CA2302700C (en:Method)
CY (1) CY1106156T1 (en:Method)
CZ (1) CZ295250B6 (en:Method)
DE (2) DE69834955T2 (en:Method)
DK (2) DK1210943T3 (en:Method)
EE (1) EE04297B1 (en:Method)
ES (2) ES2182357T3 (en:Method)
HK (1) HK1045812B (en:Method)
HU (1) HUP0003848A2 (en:Method)
ID (1) ID24838A (en:Method)
IL (1) IL134773A (en:Method)
IN (1) IN190791B (en:Method)
IS (1) IS2715B (en:Method)
MX (1) MXPA00002615A (en:Method)
MY (1) MY127812A (en:Method)
NO (1) NO327176B1 (en:Method)
NZ (1) NZ503173A (en:Method)
PL (1) PL190782B1 (en:Method)
PT (2) PT1210943E (en:Method)
RU (1) RU2199322C2 (en:Method)
SA (1) SA98190773B1 (en:Method)
SE (1) SE9703407D0 (en:Method)
SI (2) SI1210943T1 (en:Method)
SK (1) SK285330B6 (en:Method)
TR (1) TR200000726T2 (en:Method)
TW (1) TW546140B (en:Method)
UA (1) UA72446C2 (en:Method)
WO (1) WO1999015182A1 (en:Method)
ZA (1) ZA988516B (en:Method)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9703407D0 (sv) 1997-09-19 1997-09-19 Astra Ab New use
SE9802073D0 (sv) * 1998-06-11 1998-06-11 Astra Ab New use
RU2221552C2 (ru) * 1998-11-13 2004-01-20 Джаго Рисерч Аг Сухой порошок для ингаляции
US6004537A (en) * 1998-12-18 1999-12-21 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol
GB9928311D0 (en) * 1999-11-30 2000-01-26 Novartis Ag Organic compounds
GB0009584D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Pharmaceutical compositions
GB0012260D0 (en) * 2000-05-19 2000-07-12 Astrazeneca Ab Novel composition
GB0012261D0 (en) 2000-05-19 2000-07-12 Astrazeneca Ab Novel process
BR0207062A (pt) * 2001-02-06 2004-10-05 Innovata Biomed Ltd Composição farmacêutica bimodal, inalador para pó seco, método de aplicação de uma quantidade terapeuticamente eficaz de um ingrediente ativo substancialmente fino aos pulmões de um paciente, método de tratamento de um distúrbio respiratório, método de tratamento de doença pulmonar obstrutiva crÈnica (copd), uso de um agente antiinflamatório, uso de um broncodilatador, uso de uma mistura de um agente antiinflamatório e de um broncodilatador, e, processo para a fabricação de uma composição farmacêutica bimodal
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
US20030055026A1 (en) 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
SE0200312D0 (sv) 2002-02-01 2002-02-01 Astrazeneca Ab Novel composition
EP1556018A1 (en) * 2002-09-30 2005-07-27 Acusphere, Inc. Sustained release porous microparticles for inhalation
US20040121003A1 (en) * 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
US6962006B2 (en) * 2002-12-19 2005-11-08 Acusphere, Inc. Methods and apparatus for making particles using spray dryer and in-line jet mill
TWI359675B (en) 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
US7829554B2 (en) 2005-07-14 2010-11-09 Lithera, Inc. Sustained release enhanced lipolytic formulation for regional adipose tissue treatment
WO2007070843A2 (en) * 2005-12-15 2007-06-21 Acusphere, Inc. Processes for making particle-based pharmaceutical formulations for oral administration
US7913223B2 (en) * 2005-12-16 2011-03-22 Dialogic Corporation Method and system for development and use of a user-interface for operations, administration, maintenance and provisioning of a telecommunications system
GB0604141D0 (en) * 2006-03-01 2006-04-12 Arrow Int Ltd Nebulizer formulation
ES2398480T3 (es) * 2006-10-17 2013-03-19 Lithera, Inc. Procedimientos, composiciones, y formulaciones para el tratamiento de la enfermedad ocular tiroidea
US9132084B2 (en) * 2009-05-27 2015-09-15 Neothetics, Inc. Methods for administration and formulations for the treatment of regional adipose tissue
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
HUE031283T2 (hu) 2009-05-29 2017-07-28 Pearl Therapeutics Inc Nyújtott hatású muszkarin antagonisták és nyújtott hatású béta 2 adrenerg receptor agonisták pulmonáris beadására alkalmas készítmények és ezekkel kapcsolatos eljárások és rendszerek
US20110132355A1 (en) * 2009-06-09 2011-06-09 William Gerhart Treatment of chronic obstructive pulmonary disease with nebulized beta 2-agonist or combined nebulized beta 2-agonist and anticholinergic administration
CN102000090A (zh) * 2009-08-31 2011-04-06 北京利乐生制药科技有限公司 一种以布地奈德与阿福特罗为活性成分的复方制剂
WO2011088413A2 (en) * 2010-01-15 2011-07-21 Lithera, Inc. Lyophilized cake formulations
AU2011336869B2 (en) 2010-11-24 2016-09-15 Neothetics, Inc. Selective, lipophilic, and long-acting beta agonist monotherapeutic formulations and methods for the cosmetic treatment of adiposity and contour bulging
US9585930B2 (en) 2011-03-20 2017-03-07 Trustees Of Boston University Therapeutic agent for emphysema and COPD
CN102362860A (zh) * 2011-10-27 2012-02-29 江阴长风医药科技有限公司 以氢氟烷烃为抛射剂的布地奈德和福莫特罗气雾剂制剂
CN105188679B (zh) 2013-03-15 2018-10-16 珍珠治疗公司 用于微粒晶体材料的状态调节的方法和系统
ITMI20130571A1 (it) * 2013-04-10 2014-10-11 Zambon Spa Composizione farmaceutica contenente budesonide e formoterolo
WO2015065220A1 (ru) * 2013-10-28 2015-05-07 Шолекс Девелопмент Гмбх Ингаляционный препарат для лечения бронхиальной астмы и хронической обструктивной болезни легких и способ его получения
GB201321717D0 (en) 2013-12-09 2014-01-22 Pharmachemie Bv Inhalable Medicaments
GB201321712D0 (en) 2013-12-09 2014-01-22 Pharmachemie Bv Dry Powder Inhaler
GB201408387D0 (en) * 2014-05-12 2014-06-25 Teva Pharmaceuticals Europ B V Treatment of respiratory disorders
MX375783B (es) 2015-12-04 2025-03-07 Mexichem Fluor Sa De Cv Composiciones farmacéuticas que comprenden un compuesto de formoterol, un corticosteroide y un componente propelente.
CN112997256A (zh) 2018-06-14 2021-06-18 阿斯利康(英国)有限公司 使用皮质类固醇医药组合物治疗和预防哮喘症状的方法
WO2021048171A1 (en) * 2019-09-10 2021-03-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Method to improve phagocytosis
US12329759B2 (en) 2019-10-17 2025-06-17 Trustees Of Boston University Methods and compositions relating to lung function

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL95590A (en) 1989-09-08 1996-06-18 Glaxo Group Ltd Medicinal preparations containing Salmetrol and Pluticasone Propionate
EP0416950B1 (en) 1989-09-08 1993-08-11 Glaxo Group Limited Medicaments
US5250286A (en) * 1990-05-07 1993-10-05 Aegis Technology, Inc. Treatment of chronic obstructive pulmonary disease (COPD) by inhalation of an imidazoline
PL164294B1 (pl) 1990-12-20 1994-07-29 Inst Farmaceutyczny Sposób otrzymywania diastereoizomeru /22R/-16a , 17a-butylidenodioksy-11 ß 21-dihydroksy-1,4-pregnadien-3,20-dionu PL
US5795564A (en) * 1991-04-05 1998-08-18 Sepracor, Inc. Methods and compositions for treating pulmonary disorders using optically pure (R,R)-formoterol
US5444521A (en) 1991-07-15 1995-08-22 Canon Kabushiki Kaisha Image fixing device capable of controlling heating overshoot
SK282826B6 (sk) * 1991-12-18 2002-12-03 Aktiebolaget Astra Farmaceutická kompozícia na podávanie inhaláciou s obsahom formoterolu a budesonidu a jej použitie
EP1086697A2 (en) 1991-12-18 2001-03-28 AstraZeneca AB New combination of formoterol and budesonide
SE9404080L (sv) * 1993-12-28 1995-06-29 Ciba Geigy Ag Förfarande för framställning av en optiskt ren enantiomer av formoterol
US5983956A (en) * 1994-10-03 1999-11-16 Astra Aktiebolag Formulation for inhalation
SE9700134D0 (sv) 1997-01-20 1997-01-20 Astra Ab New formulation
GB9519692D0 (en) 1995-09-27 1995-11-29 Quillin Helen Atomising nozzle
PL326967A1 (en) * 1995-11-24 1998-11-09 Smithkline Beecham Spa Quinoline derivatives
SE9603669D0 (sv) 1996-10-08 1996-10-08 Astra Ab New combination
SE9700135D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
IL133597A0 (en) 1997-06-27 2001-04-30 Astra Ab New combination of antiasthma medicaments
SE9703407D0 (sv) 1997-09-19 1997-09-19 Astra Ab New use
US6598603B1 (en) * 1997-12-31 2003-07-29 Astra Aktiebolag Method for treating respiratory diseases
SE9802073D0 (sv) 1998-06-11 1998-06-11 Astra Ab New use
DZ2947A1 (fr) 1998-11-25 2004-03-15 Chiesi Farma Spa Inhalateur à compteur de dose sous pression.
US6004537A (en) 1998-12-18 1999-12-21 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol
SE9900834D0 (sv) 1999-03-09 1999-03-09 Astra Ab Novel combination

Also Published As

Publication number Publication date
EE04297B1 (et) 2004-06-15
DE69834955T2 (de) 2007-01-25
BR9812325A (pt) 2000-09-05
EP1014993A1 (en) 2000-07-05
CZ2000950A3 (cs) 2000-06-14
JP2001517630A (ja) 2001-10-09
TR200000726T2 (tr) 2000-09-21
DE69807239T2 (de) 2003-04-10
DE69834955D1 (de) 2006-07-27
HK1045812B (en) 2006-12-22
EP1210943B1 (en) 2006-06-14
US20020042404A1 (en) 2002-04-11
SK285330B6 (sk) 2006-11-03
RU2199322C2 (ru) 2003-02-27
PL339295A1 (en) 2000-12-04
MXPA00002615A (es) 2002-04-24
TW546140B (en) 2003-08-11
ID24838A (id) 2000-08-24
EP1210943A1 (en) 2002-06-05
AU757235B2 (en) 2003-02-06
ES2266322T3 (es) 2007-03-01
IN190791B (en:Method) 2003-08-23
SE9703407D0 (sv) 1997-09-19
CA2302700A1 (en) 1999-04-01
HUP0003848A2 (hu) 2001-08-28
UA72446C2 (uk) 2005-03-15
IL134773A0 (en) 2001-04-30
PT1210943E (pt) 2006-09-29
CZ295250B6 (cs) 2005-06-15
SA98190773B1 (ar) 2006-10-02
EP1014993B1 (en) 2002-08-14
SI1014993T1 (en) 2003-02-28
AR013506A1 (es) 2000-12-27
PL190782B1 (pl) 2006-01-31
IL134773A (en) 2005-03-20
NO327176B1 (no) 2009-05-04
MY127812A (en) 2006-12-29
PT1014993E (pt) 2002-12-31
CN1271287A (zh) 2000-10-25
ATE222106T1 (de) 2002-08-15
US20110097282A1 (en) 2011-04-28
DK1014993T3 (da) 2002-11-11
US20060189587A9 (en) 2006-08-24
KR20010024140A (ko) 2001-03-26
ES2182357T3 (es) 2003-03-01
ATE329599T1 (de) 2006-07-15
AU9192898A (en) 1999-04-12
US7897646B2 (en) 2011-03-01
US8461211B2 (en) 2013-06-11
NO20001401D0 (no) 2000-03-17
NZ503173A (en) 2001-08-31
IS2715B (is) 2011-02-15
CA2302700C (en) 2010-11-23
SK3892000A3 (en) 2000-12-11
SI1210943T1 (sl) 2006-10-31
IS5407A (is) 2000-03-15
EE200000145A (et) 2001-02-15
ZA988516B (en) 1999-03-19
DK1210943T3 (da) 2006-09-18
NO20001401L (no) 2000-03-17
CN1149998C (zh) 2004-05-19
WO1999015182A1 (en) 1999-04-01
DE69807239D1 (de) 2002-09-19
HK1045812A1 (en) 2002-12-13

Similar Documents

Publication Publication Date Title
CY1106156T1 (el) Νεα χρηση βουδεσονιδης και φορμοτepολης
CY1108610T1 (el) Πεπτιδια της il-2 και παραγωγα αυτων και χρηση αυτων ως θεραπευτικοι παραγοντες
BR0107691A (pt) Sapogeninas substituìdas e seu uso
CY2010018I2 (el) Ενωσεις τυπου αμινοκυκλοεξυλο αιθερια και η χρηση των
EA199800667A1 (ru) Новые фенантридины
FI20115742L (fi) Mometasonifuroaatin käyttö lääkkeen valmistuksessa
DK1104425T3 (da) Hidtil ukendte thiazolopyrimidinforbindelser
BR9814040A (pt) Agudo no pulmão com fibrose com antagonistas de avb6
DK0760848T3 (da) Lactobacillusstammer af menneskelig oprindelse, deres sammensætninger og anvendelse deraf
ATE318590T1 (de) Arzneimittelkombinationen (z.b. chlorpromazin und pentamidin) zur therapie von neoplastischen erkrankungen
PT797439E (pt) Utilizacao de pramipexote como agente neuroprotector
PT705100E (pt) Guanidinas substituidas terapeuticas
IT1285770B1 (it) Composti corticoidei
SE9604751D0 (sv) New therapy
PT1109571E (pt) Metodos de tratamento da hipertensao e composicoes para utilizacao nesses metodos
CY1111509T1 (el) Ενωσεις με ιδιοτητες απελευθερωσης αυξητικης ορμονης
ATE139226T1 (de) Aminosulfonylharnstoff-acat-inhibitoren
IS5951A (is) 5HT1 mótlyf fyrir meðferð gegn þunglyndi
BG100248A (bg) Инхибитори на скваленсинтетаза
NO20005548D0 (no) Mykobakterieinhibitorer
NO20003481D0 (no) FremgangsmÕte for behandling av COPD
DK1049468T3 (da) Anvendelse af hydroxypyridonholdige pudderpræparater til behandling af skinnebens- og tryksår
DK0952982T3 (da) Hidtil ukendte hepatitis B inhibitorer
ATE218866T1 (de) Kombinationstherapie zur behandlung von aids
DK1133297T3 (da) Ny terapeutisk anvendelse af 1,6-dimethyl-8beta-hydroxymethyl-10alpha-methoxyergolin